Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Since your doctor friend appears to be the only one who has heard of this study, it would be great if he could supply some more information on where to find the data. No trial matching your description was registered on clinicaltrials.gov and no published data appears on pubmed.
The study you are looking for doesn’t exist because management decided that it was better to use their limited funds elsewhere. And since they now have an annual sales rate of around 25 million, instead of still being in a really long expensive sepsis trial, I think they made the right decision. Now they can work on designing a sepsis trial to run when they are cash flow positive and they have a huge amount of data to draw from to help with patient selection and trial details.
You are referring to the following study fro 2011: Efficacy Study of CytoSorb Hemoperfusion Device on IL-6 Removal in ARDS/ALI Patients With Sepsis. This study involved 6hr daily treatments and it failed to produce statistically significant differences with a number of end points. Since then, as can be seen in the many case reports and other small trials, most practitioners have changed to much longer treatment periods. 12hrs up to several continuous days, using several cartridges.
The article is readily available in it's entirety on the internet, so either your claim to not be able to find it is disingenuous or you need to work on your DD skills
Seems like that would be a bad idea. The only regular possibly negative side effect noted in refresh 1 study was a transient drop in platelet count.
Last two days uner 100K were August 23rd and may 3rd 2018. These things happen from time to time.
it appears to be a WBC count with differential and blood smear from a CAR-T patient. They noted that there was low WBC count with a higher than normal portion of lymphocytes and what appeared to by activated T-cells seen on microscopic analysis. Just another small piece of evidence that cytosorb could potentially help with CRS
This disconnect is why the last year has been filled with so much opportunity for cheap buy in. Once you own it’s a double edged sword until active CRS treatments are in the works
Looks like black rock bought about $16 million worth this quarter! Maybe someone saw this update around the end of the day today.
Happy to see doctors using it in Croatia, a far way from Germany, and with good results.
SOC is always nice to hear. Would love to see some PR talking about this and any other hospitals that have made this determination.
Lactate levels are used as a marker for poor perfusion which can indicate possible sepsis. Higher levels is a worse indicator but lowering the levels wouldn’t necessarily effect the outcome.
I like that they are now starting very early. Shows that they are comfortable enough with the safety of the device that it is no longer just a last ditch option. Makes sense that they'll get better results early when there are less cytokines and other problem molecules to filter out. This also opens the door to more early intervention RCTs at hospitals where cytosorb is not yet standard of care
Ctso does their own distribution in Germany. Appears they want to keep it that way. This is where the majority of their sales are and they get much better margins selling direct to hospitals.
I'm tempering my expectations at the moment. It's only been a month of sales and this is a new product that requires explanation and probably some test orders. Decent numbers (2M+) should keep the upward momentum. Follow it up with some positive preliminary results on the US heart trial and more concrete plans for a follow up study and we should be in a good position for the strong third quarter earnings I expect to see. IMHO.
Just 4 more years ??
The $52 MM loss was for the first 6 months of the year and includes change in fair value of warrants. That's 19MM net income this quarter - 71MM loss last quarter.
Either way the numbers are totally irrelevant to the underlying performance of the company. They can mostly be attributed to changes in warrant value. What's relevant is the revenue of 525,000, with 30% year over year growth. This growth should be accelerating going forward with the newly approved test.
The income numbers will be weird like this until much more of the warrants have been exercised. Looks like worst case scenario there will be just shy of 43MM shares outstanding once all the dilution is done, but this should also be bringing in investment capital in the process. I would just use that number of shares when making my purchasing decision and look at revenue rather than net income.
Although this news should help stabilize the stock, if it wasn't for the reverse split, we would easily be back in the .30s, and probably on larger that average volume I think this was done in the wrong order.
A lot of people can't sell, because their brokerages haven't received the new shares. I would bet that those same brokerages would exercise a buy order. This would artificially favor buying pressure. That being said, we're only back to where we were right before they announced the reverse split, so some of it could just be investors betting the drop was an overreaction.
Scottrade is telling me I won't be able to trade until at least tomorrow, so that may be true for some other brokerages as well. they say that they have to receive the new shares before I can trade.
Looks like people wanna hear what he has to say.
[url]
https://twitter.com/enalrazvi/status/579999684107862016/photo/1 [/url][tag]Tweet of presentation[/tag]
Call me crazy but maybe the day before christmas eve isnt the best day to present a positive material event.
Alright. No medical terms. Look at figure 2 from the lancet article. The light green line is the immune system and the red line virus in the blood. The green goes up, the red goes down at the same time.
Doctors are taught to be very skeptical, and with good reason. Im not saying they shouldnt keep trying to use it. Im just saying that the most important data from this trial is that it appears to be safe to use and it captures viruses from the blood.
Im still long on the stock. Im just saying its ridiculus to get mad at the doctors just becuase u dont like their conclusion. The message board should be a place to discuss material events, not to cheerlead and rant about conspiracies.
If people werent going nuts about ebola, we might not have gone thru that bubble that has left potential longer term investors wary.
You're missing the most important point, the HP wasn't used until after there was a strong increase in Ebola antibodies. this is important for two reasons.
1) Opsoniztion and agglutination of the viral particles by the antibodies may have prevented them from being trapped by the filter.
2) It is very difficult to separate out the effects of the immune system vs the effects of the filter.
We need an HP treatment of a patient earlier in the course of the disease to have a chance of seeing the real effects.
The measurements for the larger drop (400,000->1000) were taken from a slightly larger time frame around the HP treatment, while the 229,000-->76,000 were taken immediately before and after. Again, this is all clouded by the overall trend in viremia levels at the time due to the ramping up of the immune response.
As I see it, Ebola levels reach astronomical levels because of the delayed immune response. The HP seems that it would be most effective as an adjunct therapy before the immune system has a chance to respond (see the low levels of ebola IgG all the way up to day 9). Hopefully we can get the opportunity to treat someone at this earlier stage.
Hey Neom, do you have access to these transcripts? I have read the Lancet article and have some concerns. I would like to hear Dr. Geigers take in his own words. The data doesn't show any negative effects from the HP (which is good data in itself), but the treatment was also started after a distinct spike in ebola antibodies. It was not incorrect for the doctors to conclude that viral loads would have likely dropped anyway. It looks to me that we would need a case in which the HP is implemented earlier, to show it's effects prior to a strong immune response. I am curious to see why Dr Geiger concluded that this was clear evidence in support of the devices efficacy in this case.
based on the capture numbers, it appears that the HP could be a great intervention much earlier in the course of the disease (at first sign of symptoms), or if used for longer treatment times. Hopefully Nebraska takes on some evacuated cases soon and uses the HP.
I am still long AEMD and currently hold 250,000 shares. However, I am holding them because of the recently started clinical trial, not because of ebola.
Looks like Maggie Fox has already edited her story. JJ told me that he sent her the original data. That was apparently enough to get her make this little edit. Would be nice if she made a public retraction as well.
Here's an excerpt from the original release:
They also tried favipiravir but the patient couldn’t hold down the pills. And they tried a blood filter made by a San Diego company called Aethlon but they said it did not work to remove virus from the patient’s blood.
It’s impossible to know which treatments helped. Like other patients who got experimental drugs, the Ugandan doctor, who asked not to be named, got the very best supportive medical care
Here's the same exerpt as it can currently (1740 PST 12/19/2014) be found on the NBC website:
They also tried favipiravir but the patient couldn't hold down the pills. And they tried a blood filter made by a San Diego company called Aethlon.
It's impossible to know which treatments helped. Like other patients who got experimental drugs, the Ugandan doctor, who asked not to be named, got the very best supportive medical care
http://www.nbcnews.com/storyline/ebola-virus-outbreak/one-more-drug-ebola-treatment-pipeline-n270576
Here are the final numbers for the ebola spending in the 2015 budget
$112 million will be appropriated to DoD for Ebola response and preparedness. Of this, $45 million will go to the Defense Advanced Research Projects Agency’s long-range research programs; $50 million to nearer-term research programs of the Defense Threat Reduction Agency; and $17 million for procurement of equipment.
$25 million will be appropriated for Ebola response and preparedness at FDA, including “increased medical countermeasure activities.”
$2.742 billion will be appropriated to HHS to respond to the Ebola epidemic in the United States and other countries threatened by the virus. Funding will be used to: (1) develop vaccines and treatments; (2) train health care workers; (3) bolster quarantine stations at ports of entry; (3) create isolation units; (4) reimburse hospitals providing care; and (5) send CDC personnel to countries affected by Ebola.
$238 million will be appropriated to the NIH for Ebola-related research.
$2.5 billion will be appropriated to DOS “to respond to the Ebola epidemic in West Africa and to strengthen public health capacity in other countries threatened by the virus.”
Here are a few potentially relevant excerpts from the 2015 omnibus appropriations bill (emphasis added). I'd have to imagine that our friends at DARPA have Aethlon at the top of their research list :)
Ebola: The bill provides $112 million for Ebola response and preparedness. Of these
funds,$45 million is directed to DARPA long-range research programs, $50 million to
nearer-term research programs of the Defense Threat Reduction Agency and $17 million
for procurement of necessary equipment.
Ebola Preparedness and Response—The bill includes $2.742 billion for responding to Ebola
and other infectious disease threats, both in the U.S. and abroad. Funding is provided for the
development of vaccines and treatments, to train hospital workers and other workers potentially
exposed to Ebola through their jobs, to bolster quarantine stations at the nation’s ports of entries,
to create isolation units on a regional basis, to reimburse hospitals spending millions for
expensive care and to send Centers for Disease Control and Prevention (CDC) scientists to help
stop the spread of Ebola where it is currently affecting the most number of people.
National Institutes of Health (NIH)—The bill provides $30.3 billion, an increase of $150
million in base funding and $238 million in Ebola-related research, to fund biomedical research
at the 27 Institutes and Centers that comprise NIH.
Ebola. $2.5 billion in emergency funding to respond to the Ebola epidemic in West
Africa and to strengthen public health capacity in other countries threatened by the virus
This is my recollection from a Q&A after a company meeting a few years ago (2011?). Below is a link to a site that sells the agent they use, galanthus nivalis lectin (GNA). I don't know who they actually buy from or how much they put in a cartridge, but as u can see it's quite expensive. This is because it's a specialty item right now, used only by a few research labs. Large scale production will have to be worked out after regulatory approval.
GNA cost
Actually, they currently get there affinity material from a company that makes it in small batches and its quite expensive.
They were working with kentucky bio to genetically modify tobacco plants to produce the agent, but last i heard they werent happy with the results yet. Cash to make the filters has been a major limiting factor. They usually only have a small number on hand and have to be very judicious with their use. This is why they just sold $3.3mil worth of shares on this bump. Now they can hopefully make all the filters they need for trials as well as emergency use
I hope You're right. I'm a little disappointed that they didn't release news of the India trial this month. Although it may be a better strategy to release it after Thanksgiving weekend
This little article is for the day traders, just in case you want to take a break from arguing about pennies and reflect on the positive impact that this company could have on the world.
http://www.newvision.co.ug/news/662188-ebola-ugandan-doctor-reunited-with-family.html
Im pretty sure its just the MM closing out all the unbalanced trades for the day. Yesterday it was almost 4million shares. This can happen with big volume on otc stocks
Here's an article on the trial that was run there: [url]www.brandindiapharma.in/pharmaceutical-blogs/medicity-and-aethlon-to-provide-hemopurifier-therapy/
This is the trial whose results we should get in the near future. You could probably contact the Medanta Medicity hospital directly to see what their current policy is. good luck.
Sounds more like cytosorbs technology to me. It relies on pathogens binding to immobilized heparin with membrane proteins they use to recognize cells they normally invade. These membrane proteins can be highly variable in different pathogens. According to the companies own website, there are several bacteria for which they had to develop alternative adsorption media.
Additionally, the blood is not filtered prior to adsorption, so they are limited to affinity agents that don't bind to blood cells or other essential blood components. The HP is limited to viruses and proteins because of the filtration process, but the affinity agent binds to more universal viral components.
If their filter works safely in humans it may be good for bacterial infections, but that's not our market, so it shouldn't be an issue.
Most importatly, they're still in the development stage and have no human trials of any type. I still think we're on the right train here
Those are fun facetious options, but if I remember correctly Obama asked congress for $6 billion for the containment and treatment of ebola. that could probably buy a cartridge or two.
As long as we're thinking wishfully, maybe the conference is set up by someone other than Aethlon. A government agency discussing it's ebola plans perhaps. Can't wait for the details.
From what I can gather, this Doctor was brought to Frankfurt on 10/3/14. This 11 day gap makes me think that AEMD waited to see convincing strides toward a positive outcome before announcing their involvement. Hopefully this also means we should get an update soon on the patient condition and maybe even some data on viral clearance by the filter. Good luck to all longs, if there are still any on the board.
Although it's not huge I think IRB approval, for this particular trial, is new news. I'm also excited to hear that they will begin enrolling participants in the next few weeks. I was a little worried by the November start time posted on clinicaltrials.gov. That would have been a long delay from the last stated start time of September. Hopefully this means things can start sooner rather than later.
I don't think too many people noticed it. There was no spike in volume. Hopefully jj tries to get the news out to a wider audience once the details of the contract are worked out.